August 25, 2022 Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
April 15, 2022 Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy
June 28, 2020 Asieris Announced the Completion of Series C+ Round Financing – to Accelerate the Commercialization
March 24, 2020 Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs
